The results of recent preclinical studies have demonstrated therapeutic approaches targeting the TGFβ signaling axis [97,98,99,100]: for example, by silencing the TGFβ2 with Trabedersen (AP 12009), which is an antisense phosphorothioate oligodeoxynucleotide for inhibiting TGFβ2 biosynthesis, Schlingensiepen et al. demonstrated that tumor growth and lymph node metastasis were significantly reduced in a metastatic pancreatic cancer mouse model [101]. This evidence concerns the gene TGFB1 and neoplasm.